The ability to choose different clinical outputs through the combination of two or more imaging approaches that can be combined for patient comfort and compliance (such that one set of investigations can be conducted in one visit). For example, multiple imaging inputs, such as anatomy and various phenotypes, can be selected to generate a specific output or multiple distinct outputs. b-d, Examples of multiplexing imaging (see also Figs. 2 and 3 ). In the current use of the terminology for cancer imaging, 'best use of expensive resource' is achieved by (1) the use of techniques such as radiomics-based de-multiplexing of PET, MRI and CT (b) or MSOT (c); or (2) multiplexing in the context of clinical activities, such as cost effectiveness of patient management, making diagnosis more accurate through innovative combinations of modalities or methods to achieve contrast, and reducing patient recall or the need for further imaging. Deriving different parameters from a single modality, for example, by using different MRI sequences to generate a combination of clinically useful information (multiparametric MRI; d) including oxygen-enhanced MRI, diffusion-weighted imaging, MR spectroscopy (MRS), dynamic contrast-enhanced MRI and associated T 1 /T 2 anatomical imaging), falls under the latter category. Images in panel a (in box 'Demultiplexer') adapted from ref. 193 under a CC0 license.
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as a "constellation of diseases with common themes" 1 . Despite the large number of different cancer types, shared molecular and metabolic phenotypes have emerged as an expansion to extensive biological research, leading to a better understanding of common processes that initiate and drive cancer development, metastasis and treatment resistance. The development of precision therapeutics in oncology 2 , and that of genomic markers of drug sensitivity 3 for example, benefit from multiplexing as a discriminant criterion, because in both cases their utility is determined by establishing a meaningful relationship between complementary signals. Targeted molecular-imaging probes have thus expanded in parallel with the increase in biomarker identification 4 . Also, characterization of the genetic basis and phenotypes of specific cancer types increasingly demonstrate their histotype-unspecific association ( Table 2) . Target specificity therefore, applied to the landscape of heterogeneity in oncogene-driven alterations and therapeutic response, highlights the need for multiplexed engineering design principles, where imaging techniques that visualize molecular dynamics maximize the sensitivity to, for example, therapeutic radiopharmaceuticals using nuclear-medical imaging modalities. Important efforts are underway to fine tune multiplexed molecular-imaging strategies and align these to highthroughput clinical diagnostic and therapeutic platforms (Fig. 1) . As the literature describing these efforts is extensive, we focus on the most recent advances in targeted molecular-imaging probes and how their translational impact can benefit from multiplexing.
To understand what benefits multiplexing brings, it is important to start with a focus on the objectives of clinical cancer imaging, which include early detection and diagnosis, differentiation of benign from malignant disease, staging, stratification for therapy selection, optimal surgical planning, objective-and early-response assessment of therapy, detection of recurrence/re-staging, as well as understanding physiology, tumour-microenvironment characteristics and tumour heterogeneity in humans. The detection limit of most anatomical imaging methods (25-50 mm 3 , equivalent to 10 6 -10 7 cancer cells 5 ) can be enhanced through multiplexing with molecular-imaging probes that show high focal uptake in tumours due to altered receptor expression or metabolism 6, 7 . In early-phase drug development in patients, multiplexing expedites the process by combining reporters for two or more pharmacological objectives: presence of target, pharmacokinetics, target engagement, modulation of downstream biochemical effects or clinical response 8 . Multiplexing facilitates the establishment of accurate dosimetry and maximizes theranostic sensitivity, enabling 'imaging stratified' therapy analogous to genetic-stratification strategies, and provides robust early surrogate endpoints of efficacy. Presurgical planning can also be linked to real-time surgical monitoring and post-surgical assessment for improved surgical resection margins. Although the above-noted uses of multiplexed imaging reduce the need for further imaging and may have clear healtheconomic benefits, it is important to note that 'no-patient-benefit' physiology studies further expand knowledge of cancer biology in situ in humans.
Notwithstanding these advantages, significant challenges exist in implementing multiplexed methods. Certain methods may not be sufficiently validated; that is, may have not crossed the two 'translational gaps' (transitioning from discovery to use in clinical hypothesistesting and then to clinical decision-making) necessary for robust and confident use 9 . The cost of multiple imaging methods is also likely to be higher, especially in the early phases of implementation. Technical hurdles complicate the registration of sequentially acquired data (especially with regard to responding tumours), and the fit to response evaluation criteria in solid tumour (RECIST) measurements need to be considered. Change of the status quo may be met with antagonism, as evidenced by the resistance to transition from diagnostically useful genomics or proteomics platforms to analogously validated imaging methodologies. Also, considering the range of multiplexed-imaging methods currently in development, there is a striking lack of robust standardized methodology to permit data comparison across centres and enable exploitation for machine learning and other big data approaches for segmentation, registration, detection and heterogeneity determination 10 . Despite these challenges, on the basis of the enhanced understanding of the complexity of cancer phenotypes, evidence-based and outcome-specific multiplexing needs to become a part of patient staging or interim re-staging workflows, and used in experimental medicine to improve efficiency, particularly because patient cohorts that benefit from significant outcome improvements now require longer monitoring periods to determine survival. Different molecular modalities and contrasts constitute the main options for channelling multiplexed information in cancer imaging.
Combining data from multiple modalities
No modality is ideal for every application, and all have inherent strengths and weaknesses germane to sensitivity, specificity, spatial resolution, temporal resolution, signal penetration, patient considerations and cost. For instance, PET generally informs on tissue phenotypes or processes (such as receptor expression [11] [12] [13] [14] [15] [16] , microenvironment 17, 18 , metabolism 16, [19] [20] [21] [22] [23] or perfusion) with outstanding sensitivity, but it is hampered by low resolution, scarcity of anatomic detail and dosimetric stipulations 24 . In contrast, MRI provides anatomic detail with exquisite resolution, but lacks the sensitivity offered by radionuclide imaging; specific aspects of individual modalities are indicated in Table 3 (refs [24] [25] [26] [27] [28] [29] [30] [31] ). The selection of complementary information using distinct imaging channels of transmission can lend incredible value in delineating and characterizing the multiple features of tumours by 
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yielding a more comprehensive pathological view of tumour structure and function [32] [33] [34] [35] [36] [37] [38] [39] [40] . Traditionally, in the case of PET-MRI, MRI provides the anatomic correlation for the quantitative functional information supplied by PET, leveraging the advantages of both the PET and MRI components to provide a sensitive and detailed spatial map of a lesion. PET-MRI is but one example. In the advancing era of precision and personalized medicine, the role of multiplexing is not only essential, but also evolving. Echoing several themes 32, 33, 41 , this section surveys applications, challenges and advances in several of the most clinically relevant examples of multiplexed-imaging strategies, and includes clinically ubiquitous approaches in modern biomedical imaging as well as strategies at the forefront of the field, but not yet in widespread clinical use.
Irrespective of the modality used, several of the single or multimodal (single or multiparametric) data including from CT, PET and MRI can be analysed and thus de-multiplexed with software to generate large numbers of 'radiomics' features analogous to genomic approaches [42] [43] [44] . Radiomics automates data quantification of the macroscopic tumour phenotype. Patterns in image space are quantified, including first-, second-and higher-order statistical features, as well as fractal-and shape-based features. The technology has many promising opportunities despite being in its infancy. It offers biomarkers for prognosis, an important consideration in patient management. In lung cancer, certain CT and PET imagederived radiomics features have been found to be associated with EGFR and KRAS gene mutations, cycling cells, prognosis, local control and distant metastasis 43, 45, 46 , thus vastly increasing multiplexing opportunities towards precision medicine. Prospective clinical trials of these radiomics outputs will further validate their use in cancer imaging.
PET-CT.
The role of PET-CT in oncology has grown immensely since the turn of the millennium, so much so that standalone PET scanners are virtually non-existent in today's market. PET brings the ability to interrogate molecular processes quantitatively in vivo with outstanding sensitivity and specificity, through coincidence detection of γ -radiation from radiotracer positron decay. CT reinforces the clinical utility of PET in several ways that enhance diagnostic accuracy: the spatio-anatomic reference given by CT assists in the generation of quantitative PET data by providing a tissue-density map to facilitate appropriate correction for attenuation effects 47 ; it assists clinicians in recognition of false-positive tracer uptake 48 ; and it assists in identifying precise tumour margins for optimal subsequent care 49 (for example, biopsy, resection or monitoring). The availability of both fluorinated small molecules, and more recently, macromolecules labelled with a variety of radiometals, has promoted further applications in PET-CT (Table 4  and Supplementary Table 1) 50,51 . Improvements in computing have also fuelled advances in practical image reconstruction, from simple filtered back projection to the now state-of-the-art fully three-dimensional iterative and timeof-flight methods. In parallel, iterative reconstruction algorithms are becoming commonplace for CT image reconstruction in current PET-CT systems, affording comparable or better patient-image quality at lower X-ray dose 52 . The recovery of triple-coincidence events (three γ -rays being detected simultaneously) and their inclusion in PET datasets also improves counting statistics for non-pure positron emitters 53 . While vast improvements in detector performance are necessary to take full advantage of triple-coincidence counting for dual-isotope PET, materials science has paved the way towards superior scintillators that combine high stopping power, enhanced light output and fast timing decay 54, 55 . Efforts are also underway to construct the first total-body PET scanner, EXPLORER, which is projected to provide a 40-fold increase in sensitivity relative to the current gold standard 56 .
PET-MRI. The sophistication of MRI, which conveys images that represent the behaviour of in vivo water protons under the imposition of a magnetic field, has had tremendous implications in oncology. PET-MRI orthogonally merges the outstanding resolution and softtissue contrast of MRI with the functional capability and sensitivity of PET. Compared with PET-CT, PET-MRI affords a significant reduction in patient exposure to ionizing radiation in addition to generally better intrinsic soft-tissue contrast [57] [58] [59] . PET-MRI delivers additional opportunities for multiplexing through the use of dualmodality radioisotope/MRI active molecular or nanoparticle-based 
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NaTuRe BIomedICal eNgINeeRINg probes, and the option of simultaneous T 1 -, T 2 -and diffusionweighted data acquisition 33, 60 . Technical challenges have complicated the clinical implementation of hybrid PET-MRI scanners and continue to limit the current state of the art. The traditional photomultiplier tubes currently required for maximum timing resolution in PET do not operate at the magnetic field strength required for optimal MRI. Therefore, truly simultaneous PET-MRI scanners (such as the Siemens' Biograph mMR) must use avalanche-photodiode or silicon-photomultiplier-based signal amplifiers whose poor timing resolution preclude the acquisition of useful time-of-flight data 54, 57 . Further, the presence of PET detectors and associated electronics within the MRI scanner bore negatively impacts the homogeneity of the magnetic field, degrading MR image quality. These current realities force a compromise between image quality and the simultaneity of the PET and MRI scans 57 . Sequential PET-MRI scanners (such as the Philips' Ingenuity TF PET/MR) instead preserve optimal performance of the PET and MRI by separating these into standalone components. The issues of patient movement between scans and increased total imaging time introduce logistical complication in this approach, which Philips attempts to minimize via engineering of the gantry system. Although compared with CT-based attenuation correction of PET data, MRI-based attenuation correction negatively impacts the quantitative accuracy of PET standardized uptake values, current directions in image data analysis involve rectification of these issues.
SPECT-CT.
SPECT-CT brings the familiar multiparametric functional and anatomic imaging capabilities of PET-CT, albeit with lower sensitivity due to signal loss from collimation, necessary to establish photon directionality in SPECT. In contrast, SPECT-CT is much more amenable to incorporation of additional degrees of multiplexing through simultaneous imaging of multiple tracers, as γ -rays from different radionuclides can be individually distinguished via energy discrimination with SPECT. SPECT also has a promising outlook as a theranostic tool, in particular in monitoring uptake of therapeutic radiopharmaceuticals (such as 90 
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Inibritumomab tiuxetan or 153 Sm-ethylenediamine tetra(methylene phosphoryc acid) (EDTMP)) for streamlined, optimized tumour dosimetry 61, 62 . Many of the advancements in PET-CT (for example, radiometal chemistry, targeting, image reconstruction, detector design and electronics) are directly applicable to SPECT-CT and vice versa; sustained improvement in these areas continues to uphold the clinical relevance and future application of SPECT-CT.
PET-OI and SPECT-OI. OI is perhaps the most versatile and rapidly evolving modality in preclinical biomedical imaging today, particularly within the context of multiplexed imaging strategies. Because of the ease of simultaneous detection of multiple OI agents and of the wide selection of available fluorophores for tracer development, OI is exceptionally amenable to multiplexing. Owing to its discrimination of different contrasts to the cellular level and the ability to image live processes, intravital fluorescence microscopy has been and will be instrumental to advance research, especially in drug discovery 63 .
Although this technique appears confined to the research arena, OI probes can combine nanomolar-level sensitivity with submicrometre resolution, enabling ultraprecise delineation of tumour margins as components of intraoperative-imaging strategies or minimally invasive endoscopic techniques 64 . Running counter to nuclear methods, contrast in OI is fundamentally dependent on the electronic characteristics of a fluorophore, namely the energies of the molecular orbitals of the fluorophore involved in the electronic transitions resulting in photon emission. Fluorophore molecular orbitals can be influenced by in vivo physiological characteristics, such as pH 65, 66 or the presence of cleavable quenching prosthetic groups 67 . These factors can be leveraged to generate 'activatable' probes, which emit a signal only when the probe is present at the target site, thereby decreasing the contrast-limiting background signal associated with so-called always-on probes.
The primary limitation in OI, most importantly for whole-body imaging, is the limited depth of penetration of photons in tissue within the visible and near-infrared (NIR) wavelengths. This issue is twofold, as incident excitation light required in traditional OI, as well as the subsequent fluorescent emission, are rapidly attenuated by tissue (albeit to a lesser extent for NIR). This renders OI an effectively semi-quantitative imaging modality, unless tomographic reconstruction techniques are used. PET and SPECT therefore constitute orthogonal complements to OI, and combining these techniques brings the ability to comprehensively and quantitatively interrogate the biology of living systems macroscopically (whole-body biodistribution via PET/SPECT) and microscopically (functional cellular imaging via OI) in the same investigation. This strategy is embodied in both sequential and simultaneous multiplexed single-modality probes, for example by imaging the DNA repair system and its inhibition by targeting the enzyme poly(ADPribose) polymerase (PARP) 68, 69 ( Fig. 2a) , as well as in multimodal nuclear OI probes, including small-molecule targeting of PARP1 in glioblastoma 70 , 111 In-diethylene triamine pentaacetic acid (DTPA)-HQ4 (refs 71, 72 ) in SPECT-OI of therapy-induced tumour necrosis, and numerous dual-labelled peptide 73, 74 , antibody 75 and nanoparticle probes 64, 76, 77 . Cerenkov luminescence, a phenomenon that occurs when a charged particle temporarily traverses a dielectric medium at super-relativistic phase velocities, can also produce intrinsic in vivo optical contrast via the generation of blue-to-ultraviolet-frequency photons [78] [79] [80] from positron and β -emissions. The resulting Cerenkov radiation is detectable with charge-coupled device cameras, and the data acquired by PET and Cerenkov luminescence imaging (CLI) 
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are largely in agreement, when light tissue penetration is taken into account. The resolution and sensitivity of CLI are inversely related, as both are dependent on the distance a β -particle travels while above the energetic threshold for Cerenkov emission (they are thus radioisotope dependent; for 18 F this distance is ~0.3 mm). Also, the sensitivity is a function of the refractive index of the tissue. The Cerenkov luminescence of isotopes traditionally used for PET imaging is poor, and the re-use of established PET tracers for CLI is therefore limited. Although frequencies produced in pure Cerenkov luminescence are heavily attenuated, limiting penetration depth and sensitivity 79, [81] [82] [83] , it is possible to shift the effective frequency of CLI-probe emission towards the NIR through the incorporation of fluorophores into CLI probes. Herein, characteristic ultraviolet-blue Cerenkov radiation is absorbed by a 
fluorophore and re-emitted at lower NIR-visible frequencies, enhancing tissue penetration and facilitating detection, and therefore increasing the utility of Cerenkov luminescence in the clinic. This phenomenon, known as Cerenkov radiation energy transfer (CRET), is an area of active research 32, [84] [85] [86] . However, to transition CRET into clinical practice, agents, compatible to both PET and CRET, will need to be approved and validated.
US-MRI.
Although non-contrast enhanced US and MRI are already well-established standalone modalities in oncology, the role of dualmodality US-MRI is growing in clinical and preclinical imaging due to several factors, including cost effectiveness, reliance on only non-ionizing radiation and the synergistic advantage of merging the high spatial resolution of MRI with the high temporal resolution of US 25, 87 . Moreover, molecularly targeted approaches overcome the traditional anatomic-only imaging limitations of US and MRI 88 . Nanoscale and microscale hybrid US-MRI probes almost exclusively build on previously successful single-modality nanoparticle and lanthanide-chelate probes for MRI and on microbubble schemes for US. The modular design of these probes facilitates fusion of magnetic-and ultrasound-contrast enhancing properties into dual-modality probes for US-MRI with tunable physical and pharmacokinetic properties [87] [88] [89] [90] [91] . The most notable applications of US-MRI for therapy include sonoporation (using microbubbles for gene or drug delivery) and MRI-guided high-intensity focused ultrasound (used for image-guided thermal ablation 92, 93 ).
PAI. PAI is currently a burgeoning area in both preclinical and clinical oncology, and is poised to significantly improve the standard of care for a large patient population by providing versatile, affordable and available technology for biomedical imaging. PAI hinges on the photoacoustic effect, wherein photothermal conversion of incident laser energy by a chromophore induces ephemeral thermoelastic expansion at the target. The resulting mechanical energy is transferred to the surrounding tissue, propagating as broadband ultrasound waves. The broadband ultrasound signal is detectable using piezoelectric sensors for subsequent tomographic reconstruction 94 . PAI provides activatable molecular contrast, which can then be superimposed on an anatomical background provided by traditional US using macroscopic or microscopic imaging configurations 95 . Some endogenous biological molecules naturally exhibit sufficient photoacoustic conversion efficiency necessary for PAI contrast (in particular haemoglobin, for probing hypoxia 96 or angiogenesis 97 ), and likewise do exogenous fluorescent dyes used in traditional molecularly targeted OI strategies 98 . However, the customizable structure and composition of nanomaterials have motivated their status as perhaps the most 'engineerable' platforms for PAI, particularly for integrating PAI with MRI, OI and therapeutic strategies. Recent years have witnessed the successful application of approaches involving metal-based (nanoparticles, nanorods, nanoshells and nanocages) and carbon-based (carbon dots, nanotubes, nanopolymers and nanovesicles) nanomaterials for targeting cell-specific antigens or the microenvironment (pH, pO 2 sensing), or for passive targeting (that is, by taking advantage of the enhanced permeability and retention effect) in PAI 94, [99] [100] [101] [102] [103] [104] [105] [106] . Although PAI is limited by tissue-penetration depth of the requisite excitation light, its clinical outlook is terrific for the early detection and monitoring of superficial or near-surface lesions, as well as those accessible via endoscopy. Moreover, contrasts with different excitation characteristics can be combined and imaged selectively using sequentially varied or multispectral illumination wavelengths in PAI -termed multispectral optoacoustic tomography (MSOT) -making it a truly 'multiplexable' technique. As such, PAI is currently being investigated in clinical trials of breast, prostate, gynaecologic and skin cancers, and also in other disease areas such as Crohn's disease 107 .
Combining data from different contrasts
With advanced scanner technology, tracer design and reconstruction algorithms, it is now feasible to maximize the information gained within one single imaging session through the simultaneous detection of multiple signals from different contrast agents. The advantages of simultaneous multi-tracer imaging are manifold, permitting optimal anatomical-functional registration, improved sensitivity, and parallel investigations of imaging phenotypes, physiology and therapeutic response without prolonging the scan time, which makes it desirable to patients, researchers and clinical-management teams. The modality at the forefront of this field has been OI [108] [109] [110] [111] . It offers the most ample and versatile array of imaging probes that can be simultaneously imaged, as small modulations in chemical design can make their emission profiles distinct while their kinetics remain comparable. Image quality and resolution can further be improved by the use of spectral unmixing algorithms and activatable probes. The successful application of these advances in multiplexing was elegantly illustrated by the profiling of two orthotopic breast-cancer xenografts based on their distinct receptor expression of epidermal growth factor receptor or human epidermal growth factor receptor 2 (HER2), using a cocktail of probes injected simultaneously 109 . However, achieving accurate quantification, delivery and scatter also need to be considered 112 , and the utility of this technique remains to be shown in clinical settings. In nuclearmedical imaging, most experience in multi-tracer imaging has been gained using differences in photon emission energy (in the case of SPECT) but also in half-life and tracer kinetics (in PET), and has focused on compound metabolism 113 , bone metastasis 114 and tissue vasculature 115 . However, most of these techniques are only capable of near-simultaneous multiplexing. This also holds true for multiparametric MRI (that is, T 2 -weighted imaging combined with diffusionweighted imaging (DWI), dynamic contrast-enhanced MRI and spectroscopic imaging) and contrast-enhanced ultrasound imaging using targeted microbubbles 116 . Although these methods can image multiple biological contrasts in the same imaging session, the acquisition is sequential. Instead, MRI fingerprinting 117 , an imaging approach where multiparametric data are acquired in a pseudorandom manner and analysed generating quantitative maps distinctive of the imaged tissue, is a multiplexing technique in accordance with its stricter engineering definition. Its potential for clinical application was shown by combining MRI fingerprinting-derived T 1 and T 2 mapping with DWI to discriminate between normal, inflamed and cancerous prostatic tissue 118 . Numerous imaging strategies have emerged for PET since its advent in the early 1980s, and examples of multi-tracer imaging using established and novel tracers have been described. In its early years, the prevailing tracers were primarily analogues of biologically active small molecules incorporating a single nonmetallic radiolabel. Small-molecule tracers continue to be well represented clinically (Supplementary Table 1 133 -based tracers are well suited to procedures involving sequential multiplexing. On the other hand, macromolecules 134 including antibodies and nanoparticles [135] [136] [137] [138] [139] [140] [141] [142] [143] [144] , generally constitute versatile agents for simultaneously multiplexed imaging and therapeutic strategies. Their pharmacokinetics are less sensitive to functionalization, and additional moieties are necessary for contrast NaTuRe BIomedICal eNgINeeRINg generation with an orthogonal technique; also, a chemotoxic component can be included while pursuing a therapeutic strategy. In addition, sophisticated pre-targeting methodologies enable the utilization of short half-life radionuclides within antibody-based imaging strategies [145] [146] [147] [148] . Decoupling the radionuclide from the antibody affords the combination of exquisite specificity of antibody vectors with the fast uptake and clearance of small-molecule tracers commonly employed to reduce radiation burden. In the present context, it should also be noted that this can enable or facilitate sequential multi-tracer PET (and simultaneous SPECT) investigations, reducing patient dose and streamlining workflow.
Newly developed probes together with existing radiopharmaceuticals (Table 4 and Supplementary Table 1 ) provide ample opportunities for multiplexing. The added value of anatomical CT or MRI to multi-tracer PET-SPECT-OI investigations is rather evident, but fewer investigations have highlighted the utility of adding a functional modality to a multi-signal methodology. PAI and US signals, for example, are detectable using the same equipment, making this pair attractive, as illustrated by a handheld hybrid US-MSOT probe for the visualization of sentinel lymph nodes and the determination of their metastatic status in melanoma; in a 20-patient clinical trial 149 , indocyanine green and melanin contrast were detected up to 5 cm in depth, and delivered 100% sensitivity and 48.6% specificity for metastatic status, as verified by histology. A similar US-MSOT system demonstrated simultaneous imaging of haemoglobin oxygen saturation and flow (Doppler US) in the vasculature of healthy human volunteers 150 , and frequency splitting in ultra-broadband optoacoustics identified inflammation parameters for the staging of psoriasis 151 . However, most state-of-the-art MSOT systems are still in prototypical design phase, which is a hurdle to regulatory approval and clinical adoption. In fact, most systems are not yet optimized for patient comfort or clinical workflow, and also lack methodology for standardization 152 . Improving staging. There are few examples of the simultaneous administration of multiple tracers for improving the accuracy of diagnosis. In patients with diverse cancer types, 18 F-FDG and 18 F-NaF can be combined in a single PET-CT scan by administering the two radiopharmaceuticals simultaneously or in sequence on the same day 153 . Positive attributes to the use of the two tracers in multiplexing are improved workflow and patient convenience, the reduced radiation exposure from the CT component, and the enhanced sensitivity for the detection of osseous lesions compared with either 18 F-FDG or 18 F-NaF alone. Other studies combining these two agents 114, 154 led to similar conclusions; this is also in line with the outcome of the combination of 18 F-FDG with 11 C-acetate in metastatic liver cancer 155 . The next step is to use the evidence base to attain inclusion in formal staging classifications and to achieve 'reimbursable' use. Recently, FDG-PET-CT was formally incorporated into standard staging for FDG-avid lymphomas as part of the Lugano classification 156 , where a bone-marrow biopsy is no longer indicated for the routine staging of Hodgkin lymphoma and of most diffuse large B-cell lymphomas. The FDA has approved 11 C-choline and 18 F-fluciclovine for use in staging recurrent prostate cancer, and 68 Ga-tetraazacyclododecane tetraacetic acid [Tyr 3 ] octreotate ( 68 Ga-DOTATATE) for staging neuroendocrine cancer. In all cases, opportunities exist for improving accuracy or for reducing the need of further imaging through multiplexing, to extend indications of imaging in the patient population.
The combined use of MRI and radiopharmaceuticals is particularly attractive in lymph-node staging of intermediate-and highrisk prostate cancer patients. In this setting, 11 C-choline-PET and, more recently, 68 Ga-prostate specific membrane antigen (PSMA)-PET have been found to be superior to anatomical imaging with MRI or CT, using laparoscopic extended lymph-node dissection as the reference standard, including the detection of subcentimetre lesions 6, 157 . DWI has similarly low-to-moderate sensitivity and high specificity as the aforementioned PET methods 158 , and it is envisaged that the combined use of a PET-MRI scanner may lead to improvements in both sensitivity and specificity; however, methodological challenges exist and will need resolving to achieve optimal outcome. Especially in diagnosis and staging of lymphomas, this hybrid technology holds great promise, and initial studies comparing FDG-PET, T 1 -weighted MRI and/or DWI 159 are ongoing, as the obtained information is complementary. For primary prostatecancer diagnosis, additional contrast agents, such as hyperpolarized 1-13 C-pyruvate, are now available in some institutions for MRI 160 , and it is envisaged that the combination of these or ultrasound techniques with PET will also improve diagnosis and staging.
Improving therapy selection. The use of tumour-tissue-based receptor profiling or gene-mutation analysis is routine in therapy selection for primary cancer, but not necessarily in the metastatic setting 161 . In some cancers, such as non-Hodgkin lymphoma, interim FDG-PET-CT is currently used to guide therapeutic options 162 , and the addition of other imaging biomarkers is likely to increase detection accuracy. For instance, the combined use of 18 F-FES and 18 F-FDG characterized the presence of molecular targets and the early objective response for both primary lesions and metastases in breast-cancer patients receiving hormonal therapy 163 . This approach may help guide de novo treatment selection or, in the case of therapy resistance due to the evolutionary loss of moleculartarget expression in metastases, provide evidence for alternative therapeutic options. A prognostic role for multiplexed FES-FDG imaging has also been shown 164 . Combined with FDG-PET or CT, imaging of HER2 with 89 Zr-trastuzumab enables heterogeneity in metastases to be determined, leading to improved re-staging, such as the detection of HER2-positive lesions, confirmed by biopsy, in patients who originally presented with HER2-negative primary breast cancer 165 . A restaging of this kind can change therapeutic options for patients, although the occasional appearance of falsepositive imaging outcomes needs to be managed.
Imaging physiology in patients.
Simultaneous assessment of multiple parameters (such as perfusion, metabolism and drug-target interactions) promises to tremendously increase the understanding of disease biology and drug resistance, and accelerate progress in therapy development. Simultaneous imaging of SPECT tracers labelled with different isotopes is feasible on the basis of the distinct gamma energies. However, because of crosstalk between energy spectra and scatter, non-trivial correction methods must be applied, and the energy resolution of scanners is continuously sought to improve this outcome 166, 167 . Despite this limitation, dual-tracer SPECT imaging is feasible using predominantly In in healthy volunteers and in diverse disease settings, and including brain imaging, cardiac imaging and cancer imaging 166, [168] [169] [170] [171] . Improved scanner technology 172 and kinetic analysis also promulgate simultaneous dual-isotope imaging in PET, as demonstrated for single-scan dual-tracer (staggered injection of 18 F-FDG and 18 F-FLT; 120 min of scan time) studies in patients with primary brain tumours 173 . In general, however, near-simultaneous (two tracer injections performed within a small, defined time window) and sequential imaging of multiple PET isotopes (two or three scans within one day) have been a mainstay in pharmacokinetic studies of labelled cancer-drug candidates 174, 175 and validation of PET tracers 113, 176 . Staggered injection of multiple short-lived radioisotopes including 15 O (half-life, 2.04 min), followed by [177] [178] [179] (Fig. 2b) and temozolomide in glioma 174, 180 (Fig. 2c) , advanced kinetic modelling such as derivation of the unit impulse response function for the correction of tissue-metabolite distribution have been employed to achieve more accurate quantification of tracer-drug levels. Notably, isotopes such as 15 O and 11 C require a cyclotron in close proximity; with the advent of PET-CT and PET-MRI, alternative contrast-enhanced CT or MRI techniques are being implemented for perfusion or blood-volume measurements to achieve similar outcomes.
An evolving multiplexing approach with potential clinical application is hyperPET -the combined use of hyperpolarized MRI and PET within a two-hour imaging window (inclusive of anatomical imaging). Hyperpolarized MRI provides the advantage of tracking metabolism over several enzymatic steps, and PET provides sensitivity. For example, spectroscopic MRI with the hyperpolarized metabolite 13 C-pyruvate and FDG-PET were performed simultaneously in dogs with prostate cancer 179, 181, 182 . High tumour glycolysis was detectable via the increased relative conversion of 13 C-pyruvate to 13 C-lactate ( ) with other techniques evaluating tissue acidity 183 and carbonic anhydrase-IX expression [184] [185] [186] could improve the understanding of the relationship between pH of tumour tissue and its microenvironment, and could potentially lead to the clinical translation of these agents. The concept of hyperPET is in its infancy, and critical-use criteria, which may involve combination of spectroscopic imaging with other PET agents, are yet to be defined. In addition, acceptance into routine clinical use will depend on cost considerations for multiple contrasts and on access to different types of good-manufacturing-practice facilities. One major challenge of hyperpolarized MRI and PET is the limited spatial resolution, especially in relation to tumour heterogeneity. For example, it is known that the resolution of clinical PET is much bigger than the distance over which the oxygenation status of tissue varies (5 mm versus < 100 μ m) 187 . Hence, resolution challenges affect studies investigating the potential correlation of tracer uptake and hypoxia. However, multiplexed imaging, employing pixel-by-pixel analysis and autoradiography 188 , promises to further the understanding of micro-regional heterogeneity, which is particularly important for radiotherapy planning and resistance management.
Nanoparticles can be engineered to enhance intrinsic chemical differences between normal tissue and cancer tissue, or to directly provide molecular information. Silica and gold nanoparticles are the most versatile, and have been shown to, for example, exploit surface-enhanced Raman scattering to provide super-enhancement of Raman spectra; such intrinsically multiplexed datasets enabled the endoscopic detection of flat pre-cancerous polyps 189 . Also, there are several nanoparticles for MRI that provide molecular contrast in pre-clinical development, including those with complex design such as dual 'clickable' CXC chemokine receptor type 4-targeting and matrix metalloproteinase-2/9-sensing nanoparticles 190 ; however, there is a paucity of nanoparticles in clinical use, alone or with nuclear imaging methods. Clinically approved nanoparticles 191 still face challenges in design, as nanoparticle-based tracers are typically toxic and have low contrast mainly due to unfavourable pharmacokinetics. Data on parameters such as the effective cut-off for renal glomerular-filtration size 192 may facilitate the transition of nanoparticles into clinical practice.
Combining imaging and therapy
The quintessential function of molecular imaging in oncology is to provide an accurate diagnosis so that optimal therapeutics may be applied. However, this blueprint has considerably expanded in recent years from its foundations in post-imaging resection and monitoring of patient response to chemotherapeutic or radiotherapeutic intervention. Although these remain relevant and effective methodologies for the treatment of many cancers, the current vanguard for patient care is characterized by the personalization of treatment strategies. Within this context, the convergence of imaging and therapy increasingly incorporates into the clinical workflow a combined pre-therapy imaging step, based on molecular, biophysical and anatomical information, and on analogous imaging during therapy (for example, real-time intraoperative imaging, image-guided radiotherapy or targeted radionuclide/ biological therapy), enabling precision treatment of cancers with complex molecular or microenvironmental characteristics, or in proximity to critical organs or tissues. Critical for achieving advances in cancer therapy are the requirements for accurate registration, segmentation and motion compensation using machine-learning and deep-learning algorithms that can rapidly 'decode' multiplexed outputs (Fig. 1a) 193 . The flexibility of bioconjugates and nanomaterials is also extendable to forge constructs that incorporate cytotoxic components for therapy. The diversity of available and developing therapeutic strategies is extensive, and their combination with a complementary imaging counterpart -the theranostic arena -is even wider in scope. Therefore, we focus on the developments of multiplexed strategies based on promising therapeutic archetypes spearheading growth in oncology.
Intraoperative imaging. The infiltrative nature of certain cancers often results in diffuse tumour margins, which both convolute resective surgery and obfuscate the assessment of the extent of resection. Intraoperative imaging probes directly translate the benefits of molecular imaging to the operating room, giving surgeons a real-time or near-real-time molecular viewpoint of tumour structure. This is particularly advantageous in the resection of tumours with irregular or non-distinct boundaries, especially when healthy tissue must be conserved to the largest extent possible (for example, in glioma) to minimize functional impairment 194 . Moreover, significant morphological deformation may be induced when preoperatively imaged tissues are subject to manipulation (from surgical wires or clamps, for instance), compromising the effective accuracy of pre-operative images.
The origins of intraoperative imaging trace back nearly seven decades, where Geiger-Müller detection of 32 P-phosphate uptake was used for the radio-guided localization of brain lesions 195, 196 . Today, radio-guided methods remain a viable clinical tool for both resection (for example, radioimmuno-guided surgery in colorectal 197 and brain cancer 198 ) and biopsy (for example, 99m
Tc colloids for sentinel lymph node biopsy in breast cancer) 196, 198, 199 . An underlying strength of radionuclide imaging is that pre-surgical imaging and radio-guided surgery can be conducted with the same probes. The true potential of γ -guided approaches can be realized through intelligent engineering of probes for intraoperative detection coupled with rational tracer design, exemplified by the development of an intraoperative β --emitting probe that sidesteps contrast-limiting γ -background from nearby healthy tissue. In a coupled approach, 68 Ga-tetraazacyclododecane tetraacetic acid [Tyr 3 ] octreotide (DOTATOC) was administered for pre-surgical PET, followed by β --emitting 90 Y-DOTATOC for intraoperative detection, resulting in intraoperative imaging of colorectal cancer conducted with increased sensitivity and minimal additional radiation burden for the patient compared with γ -guided surgery 198 . Alternatively, Cerenkov emission from PET probes can be harnessed via CLI for intraoperative applications, as shown in a preclinical demonstration where 89 Zr-desferrioxamine B (DFO)-trastuzumab CLI guided tumour resection following PET 81 (Fig. 3a) . Through the adoption of principles and technology from radionuclear methods, MRI, OI and US, modern intraoperative strategies have evolved considerable sophistication. Intraoperative MRI NaTuRe BIomedICal eNgINeeRINg (iMRI) has significantly impacted neurosurgery, where the benefits of high resolution, up-to-the-minute images are apparent 194, [200] [201] [202] [203] . The value of iMRI in glioma resection was demonstrated in a parallel-group trial, with complete tumour resection achieved in 96% of the 24 patients who received iMRI-assisted surgery compared with 68% of the 25-patient control group who received non-assisted surgery (P = 0.023) in the randomized trial 203 . In a similarly designed 1,003-patient trial, guided US-MRI-fusion biopsy diagnosed 30% more (P < 0.001) high-risk prostate cancers than standard biopsy 204 . Supplemented by developments in OI, the use of intraoperative optical imaging (iOI) is also expanding in the clinic. OI is intrinsically well-suited to surgical inspection, with the wide use of indocyanine green and fluorescein sodium, for example in angiography, where tissue penetration of photons is not a limitation. Current state-of-the-art iOI, however, is rooted in electronic detection and readout that simultaneously integrate wide-field and subcellular imaging capabilities into normal surgical workflow, enabling the identification and resection of bulk tumour tissue as well as microscopic groups of cancer cells 205 . Magnetic-resonance-guided focused ultrasound (MRgFUS) surgery is a notable newcomer to the intraoperative therapeutic landscape and redefines the boundaries of traditional surgical intervention. In this approach, noninvasive application of coincident, focused sound waves induces local hyperthermic ablation, which is monitored in real time via MRI. MRgFUS is currently in clinical trials for uterine, breast, prostate and malignant bone cancers. Photothermal therapy operates similarly, though generally through absorption of NIR photons by an exogenous agent to 
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NaTuRe BIomedICal eNgINeeRINg induce hyperthermia 102, 206, 207 . As photothermal therapy is typically ablative, it is arguably best classified as surgery.
Imaging and chemotherapy. For many cancer types, standardof-care remains anchored in or supplemented by traditional chemotherapy, wherein treatments are contingent on nonspecific intracellular accumulation of chemical toxins in rapidly dividing cell populations. Molecular imaging provides early-response assessment 208 , chemotherapy monitoring 209 , as well as prognostic insight 210 ; for these purposes, to date, no agent has rivalled the importance and ubiquity of 18 F-FDG. The principal disadvantage of traditional chemotherapy is the collateral damage to actively dividing healthy tissue (such as the intestinal epithelium) due to the absence of selectivity. Modern molecularly targeted chemotherapeutics remediate this drawback by leveraging the specificity of biomolecular vectors to accumulate chemically cytotoxic or cytostatic agents at the tumour site. This paradigm broadly encompasses several promising anticancer strategies, including immunotherapy 211, 212 , gene therapy 213, 214 , photodynamic therapy 84, 206, 215 and biomolecule-drug conjugates 216, 217 . In these contexts, knowledge of molecular pathophysiology of the malignancy is a prerequisite for the selection of effective therapy. Currently, pathological evaluation heavily relies on molecular profiling following biopsy, which provides an incomplete view of heterogeneous tumour physiology. Moreover, the invasiveness of the procedure is often burdensome for patients and clinicians alike, particularly when repeated procedures are required. Multiplexed molecular imaging instead provides a comprehensive, noninvasive view of tumour pathology and anatomy, and enables the rational selection of therapy, as well as insight into the optimal dosage, early-response assessment and subsequent treatment planning 143, 208, [218] [219] [220] . For example, multiplexed PET in the early-response assessment of mice to vascular endothelial growth factor 121/rGel therapy in a breast-cancer model 220 where the 18 F-labelled dimeric cyclic RGDyK peptide 18 F-FPPRGD2, 18 F-FMISO, 18 F-FLT, and 18 F-FDG were administered before and after treatment. 18 F-FPPRGD2 (decrease), 18 F-FMISO (increase) and 18 F-FLT (decrease) not only indicated therapeutic response; the magnitude of the response was indicative of the relative effectualness of the imaging strategies interrogating hypoxia and angiogenesis, over proliferation, while 18 F-FDG indicated no measureable response. More recently, FDAapproval of 68 Ga-tetraazacyclododecane tetraacetic acid (DOTA)-peptide and the development of cyclotron-generated [221] [222] [223] [224] [225] ( Fig. 3b) .
Parallel paths of innovation in ultrasound and nanomedicine have spurred the development of a host of techniques in therapeutics, including focused-ultrasound-induced drug release and MRI-guided drug delivery 88, 91, 213, [226] [227] [228] , such as chemotherapy of lymph-node metastasis in rabbits following MRI-ultrasoundguided release of doxorubicin encapsulated within superparamagnetic microbubbles 228 .
Imaging and radiotherapy. Radiotherapy focuses cytotoxic radiation on malignancies, albeit via different mechanisms. These can be broadly classified into two main categories: targeted radionuclide therapy and external beam therapy (EBT). Consonant with the methodology of targeted chemotherapy, targeted radionuclide therapies localize cytotoxic radiation (in particular, α , β -and Auger/ conversion electrons) at tumour sites via uptake of radionuclidebearing analogues of relevant biological vectors; that is, radiation is internally physiologically focused. Thus, the role of molecular imaging in radionuclide therapy is primarily for physiological assessment. In contrast, EBT physically aims a linear beam of radiation (an X-ray, electron or proton from a linear accelerator; LINAC) towards a tumour. Therefore, dose-deposition accuracy directly correlates with the stringency of requirements for optimal patient positioning. This highlights the emerging role of multiplexing in image-guided radiotherapy, particularly with high-precision intensity-modulated X-ray and proton-based approaches (Fig. 3c) . Due to anatomical changes stemming from patient movement (such as breathing or digestion), imaging is ideally conducted in real time 229 ; in fact, the use of advanced real-time image-guided radiotherapy is rapidly growing through the development of MRI-LINAC [230] [231] [232] [233] and PET-LINAC 234 systems. Advances in accelerator-based isotope production and radiochemistry have broadened the range of bespoke radiopharmaceuticals for personalized nuclear medicine beyond anatomy by enabling access to a number of diagnostic and therapeutic radionuclides. Of these, 'theranostic pair' radionuclides, comprising a positron-or γ -emitting diagnostic nuclide and an α -, β --or Auger/conversion-electron-emitting therapeutic complement (such as the isotopologues 64 235 . The high linear energy transfer of α -particles concentrates the high cytotoxic potential of α -emitting radionuclides (such as 225 Ac, 211 At or 213 Bi) within several cell diameters. This has stimulated intense interest in targeted alpha therapy for micrometastatic lesions, leukaemia and adjuvant radiotherapy, wherein extended attenuation tracks of β -radiation reduce therapeutic efficacy and increase non-target toxicity [236] [237] [238] [239] . In clinical therapy of refractory neuroendocrine liver metastases after 90 Y/ 177 Lu-DOTATOC (β -) radionuclide therapy, remission was achieved following treatment with 213 Bi-DOTATOC 240 . Several therapeutic α -emitters (such as 225 Ac and 224 Ra) emit multiple α -particles in their decay chains, offering additional cytotoxic potential; however, this can present complications due to the recoil-induced release of radioactive daughters from the targeting vector, inducing considerable nontarget toxicity. Two notable approaches have been used to combat this handicap: rapid internalization of the parent radionuclide at the target (for example, 225 Ac-trastuzumab) 239 , or sequestration of daughter radionuclides within a nanocarrier (for example, 225 Ac-doped [La 0.5 Gd 0.5 ]PO 4 @GdPO 4 @Au) 238 . Both approaches can be supplemented with molecular imaging, although activities used for 225 Ac-therapy are impractical for SPECT imaging. Alternatively CLI could be used as shown for in vivo preclinical imaging of 225 Ac-DOTA-c(RGDyK) 241 and conjugation of these therapeutics with positron-or γ -emitting nuclides for PET and SPECT is possible as well.
Boron neutron capture therapy (BNCT) is an emerging anticancer technology that effectively combines radionuclide therapy and external beam irradiation. BNCT therapeutics localize 10 B at sites of malignancy through specific targeting or preferential accumulation. Subsequent focused neutron irradiation induces NaTuRe BIomedICal eNgINeeRINg the neutron capture by 10 B nuclei, forming an excited nuclear state of 11 B ( 11 B*). 11 B* immediately decays via α -emission, simultaneously inducing a high linear energy transfer and a 7 Li recoil. In essence, this constitutes a way of achieving 'activatable' high linear energy transfer radiotherapy. In a landmark study, BNCT using liposomal delivery of 10 B significantly reduced tumour growth in a preclinical EMT6 model of mammary adenocarcinoma 242 . As in EBT, beam positioning is a critical element in BNCT. Image-guided BNCT remains an area of active research, and current methods include prompt γ -spectroscopy (enabled by 478 keV γ -emission of 7 Li) and the incorporation of diagnostic nuclides or magnetic components into boron delivery vehicles for PET, SPECT and MRI 243 .
Outlook
When should multiplexing be considered? Given the breadth and technological richness of modalities and probes for multiplexed approaches, and their potential to add complementary information to both research and clinical practice, it is evident that, in the right context, multiplexing can be extraordinarily valuable. In general, the combination of two tracers in one investigation has several advantages: increased sensitivity resulting from the use of two complimentary techniques, the fact that one tracer with two moieties is set to gain faster approval than two separate agents, and that compounds with interchangeable moieties (detectable by more than one modality) could make personalized imaging more accessible to a broader patient population. However, translational research in molecular imaging has focused on combining imaging with therapy. Indeed, we must caution and stress that in many cases, the use of a single modality resulting in a single endpoint provides the necessary information for accurate clinical assessment. Therefore, the benefits of the additional information gained from multiplexing must be weighed carefully against the implications for patient comfort, logistics and cost. This is not a trivial task. In Box 1 we provide several relevant questions to illustrate this from both clinical and preclinical-research standpoints.
The choice of whether to use multiplexing ultimately remains in the hands of the physician, who should not lose sight of the following ideals: to make procedural selection led by evidence, enshrined in quantitative output-determined standard operating procedures (including appropriate data storage for future mining); to ensure that the combined activity is cost effective, making diagnosis more accurate through innovation; and to reduce patient recall or need for further imaging. Significant challenges remain then to define and develop a standardized framework for the assessment of potential patient benefits, and to link the framework with specific modality and probe indications. Such a framework should be adaptable to the changing landscape of modalities and probes for multiplexing to beneficially translate decades of imaging innovation for improved patient assessment and therapy. In this undertaking, specialized centres at larger universities and research institutes will be required to take the lead. It will then depend on funding bodies and policymakers to implement change of clinical practice, making technology accessible to a wider patient population.
Box 1 | Questions to consider when assessing the use of multiplexed imaging in clinical and research settings.
Most of the advantages that multiplexed imaging provides need to be weighed by the logistical complexity and costs of their implementation. The following questions reflect the clinical and scientific-performance benefits and disadvantages that should typically be considered before using multiplexed imaging.
For use in clinical practice:
(1) Is complementary information gained? (2) Is the complementary information 'critical' or 'nice to have'? (3) Is the information patient dependent or is knowledge transferable once established? (4) How will patient comfort be affected? (5) Do imaging data provide an early indicator that a specific therapy will be effective or ineffective, and therefore could impact on clinical decision-making? (6) Are the logistics feasible? Are all components readily available? Can existing or future equipment be integrated? Is there any effect on throughput? (7) Is it cost-effective, or can the same information be obtained using cheaper or faster methods? (8) Will the information provide scientific output, that is, mechanism of action, or efficacy or drug-resistance information? (9) Where will efficiency gains, beyond those directly arising, come from? These could include the potential impact of machine-learning, modelling, advanced multi-tracer image analysis, innovative chemical scaffolds incorporating imaging and cytotoxic radioisotopes, and to fast-track regulatory approval. For use in research and development:
(1) Is the compound getting to the site of action in the required concentration (target drug exposure, perfusion, interstitial fluid pressure)? (2) What is the spatial heterogeneity? (3) What is the clearance rate and route? (4) How do these parameters relate to the biochemistry and physiology of the disease? (5) Will the information speed up drug development?
